Our monoclonal antibodies are designed to target the tumor without harming healthy cells.
Our unique platform, combined with breakthroughs in biotechnology, enable us to produce targeted antibodies that weren’t possible just a few years ago.
We have the advantage of owning a library of cancer vaccines, several of which have demonstrated success in human trials.
Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products. The company’s therapeutic program is focused on developing new drugs that can improve outcomes, extend survival, and improve the overall quality of life. The goal of the diagnostic program is to develop products that will enable earlier detection, and the potential for earlier intervention. Our current clinical trials are directed toward patients with late-stage pancreatic and colorectal cancer.